个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Expert consensus on the use of omalizumab in chronic urticaria in China.

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhao Zuotao[1,2,3,*1] * ; Cai Tao[4] ; Chen Hong[5] ; Chen Liuqing[6] ; Chen Yudi[7] ; Gao Xiang[8] ; Gao Xinghua[9] ; Geng Songmei[10] ; Guo Yinshi[11] ; Hao Fei[12] ; Hao Guodong[13] ; Hu Yan[14] ; Jin Hongzhong[15] ; Jin Zhehu[16] ; Li Chengxin[17] ; Li Haili[18] ; Li Jie[19] ; Li Yanming[20] ; Liang Yunsheng[21] ; Liu Guanghui[22] ; Liu Qiang[23] ; Long Hai[24] ; Ma Lin[25] ; Shang Yuanyuan[26] ; Song Yuxin[27] ; Song Zhiqiang[28] ; Su Xiangyang[29] ; Sui Haijing[30] ; Sun Qing[31] ; Sun Yuemei[32] ; Tang Jianping[33] ; Tong Xunliang[20] ; Wang Huiying[34] ; Wang Gang[35] ; Wang Lianglu[36] ; Wang Siqin[37] ; Xiang Li[38] ; Xiao Ting[9] ; Xie Zhiqiang[39] ; Ye Leping[40] ; Yu Yongmei[41] ; Zhang Chunlei[39] ; Zhang Litao[42] ; Zhang Shuchen[43] ; Zheng Rui[44] ; Zhi Lili[45] ; Zhou Wei[46] ; Zou Ying[47] ; Maurer Marcus[1,48,*2] ;
机构： [1]Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China. [2]Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. [3]National Clinical Research Center for Skin and Immune Diseases, Beijing, China. [4]Department of Dermatology and Venerology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. [5]Department of Dermatology and Venerology, Tianjin People's Hospital, Tianjin Union Medical Center, Tianjin, China. [6]Department of Dermatology and Venerology, Wuhan No.1 Hospital, Wuhan, China. [7]Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. [8]Department of Allergy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. [9]Department of Dermatology and Venerology, The First Hospital of China Medical University, Shenyang, China. [10]Department of Dermatology and Venerology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [11]Department of Allergy, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China. [12]Department of Dermatology and Venerology, The Third Affiliated Hospital of Chongqing Medicine University, Chongqing, China. [13]Department of Allergy, Tangshan Gongren Hospital, Tangshan, China. [14]Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, China. [15]Department of Dermatology and Venerology, Peking Union Medical College Hospital, Chinese Academy Medical Science, Peking Union Medical College, Beijing, China. [16]Department of Dermatology and Venerology, Yanbian University Hospital (Yanbian Hospital), Jilin, China. [17]Department of Dermatology and Venerology, The First Medical Center, Chinese PLA General Hospital, Beijing, China. [18]Department of Ophthalmology, Peking University First Hospital, Beijing, China. [19]Department of Dermatology and Venerology, Xiangya Hospital Central South University, Changsha, China. [20]Department of Respiratory and Critical Care Medicine, Bejing Hospital, Beijing, China. [21]Department of Dermatology and Venerology, Dermatology Hospital of Southern Medical University, Guangdong Provincial Dermatology Hospital, Guangdong, China. [22]Department of Allergy, ZhongNan Hospital of Wuhan University, Wuhan, China. [23]Department of Dermatology and Venerology, The Second Hospital of Hebei Medical University, Shijiazhuang, China. [24]Department of Dermatology and Venerology, The Second Xiangya Hospital of Central South University, Changsha, China. [25]Department of Dermatology and Venerology, Beijing Children's Hospital Capital Medical University, Beijing, China. [26]Department of Dermatology and Venerology, General Hospital of Ningxia Medical University, Yinchuan, China. [27]Department of Allergy, Harbin Children's Hospital, Harbin, China. [28]Department of Dermatology and Venerology, The First Affiliated Hospital of Third Military Medical University, Chongqing, China. [29]Department of Dermatology and Venerology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. [30]Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, China. [31]Department of Dermatology and Venerology, Qilu Hospital, Shandong University, Jinan, China. [32]Department of Allergy, Yantai Yuhuangding Hospital, Yantai, China. [33]Department of Dermatology and Venerology, Hunan Children's Hospital, Changsha, China. [34]Department of Allergy, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. [35]Department of Dermatology and Venerology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. [36]Department of Allergy, Peking Union Medical College Hospital, Beijing, China. [37]Department of Allergy, Henan Provincial Peoples Hospital, Zhengzhou, China. [38]Department of Allergy, Beijing Children's Hospital Capital Medical University, Beijing, China. [39]Department of Dermatology and Venerology, Peking University Third Hospital, Beijing, China. [40]Department of Paediatrics, Peking University First Hospital, Beijing, China. [41]Department of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, China. [42]Department of Dermatology and Venerology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China. [43]Department of Allergy, Tongji Medical College, Huazhong University of Science& Technology, Wuhan, China. [44]Department of Dermatology and Venerology, The First Hospital of Shanxi Medical University, Taiyuan, China. [45]Department of Allergy, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Shandong Institute of Respiratory Diseases, Jinan, China. [46]Department of Paediatrics, Peking University Third Hospital, Beijing, China. [47]Department of Dermatology and Venerology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China. [48]Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany.
出处：
DOI： 10.1016/j.waojou.2021.100610
ISSN：

摘要：
Chronic urticaria (CU) is a debilitating skin disease that lasts for more than 6 weeks with wheals and/or angioedema, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). In China, the prevalence of this disease is high, more than 1%, and on the rise. CU has a major impact on the quality of life (QoL) of patients who frequently experience sleep disturbance, depression, and anxiety. Nearly one-third of patients with CSU, in China, are resistant to second-generation H1-antihistamines (sgAHs), even at a fourfold dose (second line; off-label). Omalizumab is approved for the treatment of CSU treatment in Europe and shows remarkable efficacy and safety. In China, regulatory approval for the use of omalizumab is pending, and its use in clinical practice varies widely. Consensus on omalizumab CU treatment in China is urgently needed. The aim of this article is to propose a practical omalizumab treatment algorithm for the management of antihistamine-resistant CSU and CIndU in adults and special population including children and adolescents, and pregnant or breast feeding women, to guide daily clinical practice in China. In the development of this consensus, an expert group including mainly dermatologists, allergists, but also pulmonologists, ENTs, immunologists, and pediatricians in Allergic Disease Prevention and Control Committee, Chinese Preventive Medicine Association, reviewed the existing evidence and developed consensus on the use of omalizumab in CU patients from China. The goal of this consensus is to assist clinicians in making rational decisions in the management of refractory CU with omalizumab. The key clinical questions covered by the treatment algorithm are: 1) Omalizumab treatment routine strategy in both CSU and CIndU patients; 2) Recommended dose and treatment duration for different age stratification; 3) Treatment duration for CU patients with other allergic comorbidities; 4) Recommendation on omalizumab stopping strategy.© 2021 The Authors.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 3 区 医学
小类 | 3 区 过敏 3 区 免疫学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 过敏 2 区 免疫学
JCR分区：
出版当年[2021]版：
Q2 ALLERGY Q2 IMMUNOLOGY
最新[2023]版：
Q2 ALLERGY Q2 IMMUNOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China. [2]Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. [3]National Clinical Research Center for Skin and Immune Diseases, Beijing, China. [*1]Department of Dermatology and Venereology, Peking University First Hospital, Xishiku Avenue No. 8, Beijing, PR China
通讯作者：
通讯机构： [1]Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China. [2]Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. [3]National Clinical Research Center for Skin and Immune Diseases, Beijing, China. [48]Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany. [*1]Department of Dermatology and Venereology, Peking University First Hospital, Xishiku Avenue No. 8, Beijing, PR China [*2]. Dermatological Allergology, Allergie-Centrum- Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117, Berlin, Germany
推荐引用方式(GB/T 7714)：
Zhao Zuotao,Cai Tao,Chen Hong,et al.Expert consensus on the use of omalizumab in chronic urticaria in China.[J].WORLD ALLERGY ORGANIZATION JOURNAL.2021,14(11):doi:10.1016/j.waojou.2021.100610.
APA：
Zhao Zuotao,Cai Tao,Chen Hong,Chen Liuqing,Chen Yudi...&Maurer Marcus.(2021).Expert consensus on the use of omalizumab in chronic urticaria in China..WORLD ALLERGY ORGANIZATION JOURNAL,14,(11)
MLA：
Zhao Zuotao,et al."Expert consensus on the use of omalizumab in chronic urticaria in China.".WORLD ALLERGY ORGANIZATION JOURNAL 14..11(2021)

资源点击量：56914 今日访问量：2 总访问量：1772 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)